Bibliography for PHAYM055: Pharmacology 1 (Masters Level): Pharmacology and CNS disorders BETA

Atwood, B.K., Straiker, A. and Mackie, K. (2012) ‘CB2: Therapeutic target-in-waiting’, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 38(1), pp. 16–20. Available at: https://doi.org/10.1016/j.pnpbp.2011.12.001.

Balon, R. (2006) ‘Mood, anxiety, and physical illness: body and mind, or mind and body?’, Depression and Anxiety, 23(6), pp. 377–387. Available at: https://doi.org/10.1002/da.20217.

Brisbare-Roch, C. (2007) ‘Promotion of sleep by targeting the orexin system in rats, dogs and humans’, 13(2), pp. 150–155. Available at: http://www.nature.com.libproxy.ucl.ac.uk/nm/journal/v13/n2/pdf/nm1544.pdf.

Carlos H. Schenck, M.W.M. (2005) ‘Insights from studying human sleep disorders’, 437(7063), pp. 1279–1285. Available at: http://www.nature.com.libproxy.ucl.ac.uk/nature/journal/v437/n7063/pdf/nature04287.pdf.

Carvalho, A.F. and Van Bockstaele, E.J. (2012) ‘Cannabinoid modulation of noradrenergic circuits: Implications for psychiatric disorders’, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 38(1), pp. 59–67. Available at: https://doi.org/10.1016/j.pnpbp.2012.01.008.

Cera, N., Tartaro, A. and Sensi, S.L. (2014) ‘Modafinil Alters Intrinsic Functional Connectivity of the Right Posterior Insula: A Pharmacological Resting State fMRI Study’, PLoS ONE, 9(9). Available at: https://doi.org/10.1371/journal.pone.0107145.

Cryan, J.F. and Kaupmann, K. (2005) ‘Don’t worry “B” happy!: a role for GABAB receptors in anxiety and depression’, Trends in Pharmacological Sciences, 26(1), pp. 36–43. Available at: https://doi.org/10.1016/j.tips.2004.11.004.

Eric J. Olson, K.R. (2013) ‘Management of common sleep disorders’, 88(4), pp. 231–238. Available at: http://www.aafp.org/afp/2013/0815/p231.pdf.

Freund, T.F. (2003) ‘Interneuron Diversity series: Rhythm and mood in perisomatic inhibition’, Trends in Neurosciences, 26(9), pp. 489–495. Available at: https://doi.org/10.1016/S0166-2236(03)00227-3.

H. Attarian, O.A. (no date) ‘Treatment of disorders of hypersomnolence’, 16(9), pp. 302–302. Available at: http://download.springer.com/static/pdf/61/art%253A10.1007%252Fs11940-014-0302-9.pdf?auth66=1414068132_049751e80fe3aa485ba574ca1df01580&ext=.pdf.

Hill, A.J. et al. (2012) ‘Phytocannabinoids as novel therapeutic agents in CNS disorders’, Pharmacology & Therapeutics, 133(1), pp. 79–97. Available at: https://doi.org/10.1016/j.pharmthera.2011.09.002.

Holmes, A. et al. (2003) ‘Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders’, Trends in Pharmacological Sciences, 24(11), pp. 580–588. Available at: https://doi.org/10.1016/j.tips.2003.09.011.

Hoyer, D. and Jacobson, L.H. (2013) ‘Orexin in sleep, addiction and more: Is the perfect insomnia drug at hand?’, Neuropeptides, 47(6), pp. 477–488. Available at: https://doi.org/10.1016/j.npep.2013.10.009.

Kalueff, A.V. and Nutt, D.J. (2007) ‘Role of GABA in anxiety and depression’, Depression and Anxiety, 24(7), pp. 495–517. Available at: https://doi.org/10.1002/da.20262.

Kilduff, T.S. and Peyron, C. (2000) ‘The hypocretin/orexin ligand–receptor system: implications for sleep and sleep disorders’, Trends in Neurosciences, 23(8), pp. 359–365. Available at: https://doi.org/10.1016/S0166-2236(00)01594-0.

Levine, J. et al. (2001) ‘Anxiety disorders and major depression, together or apart’, Depression and Anxiety, 14(2), pp. 94–104. Available at: https://doi.org/10.1002/da.1051.

Luscher, B., Shen, Q. and Sahir, N. (2011) ‘The GABAergic deficit hypothesis of major depressive disorder’, Molecular Psychiatry, 16(4), pp. 383–406. Available at: https://doi.org/10.1038/mp.2010.120.

Mahowald, M.W. and Schenck, C.H. (1992) ‘Dissociated states of wakefulness and sleep’, Neurology, 42 Suppl. 6, pp. 44–52. Available at: http://ovidsp.uk.ovid.com/sp-3.29.1a/ovidweb.cgi?QS2=434f4e1a73d37e8cfb45f8f3b30e414ee9c0a99335d397e159343d518000931b3c02776b3f73d5a73a4476c2679e970eef9ae15361c4ac577ac7741a1d63634ffba5cef7d6361f976830f426efde734282833d172499d85065998d528dfa9b0a1521d75a5793939995cf8636d6af8a033f8955aa9e537d33ba711609a51d940e69485e1ed697cf1dadc84e2eb68e50c7e93be01be19eed6df41603840c5460e69cc207bc2ddbc6eb8c2189f3a42a831e6ad6a1f92d7fa7471c844690e98333819a6b31708033f7fb585a0e12b8a8ff8a4b15631fb49b82364902e6f027e3eebcba970b2989190824afdb921b41b4cbf09a5f9664093d267e01ea7087c5e48493339b1f5c17aed68251a3a1acd20e242d6f05b7bf22829494401b04044f2cd3299f2879d54f2227f13dbe1ffabb7a65b8acf2bc24807530aa2899ef11384d1b4fbf3817896b409736f1feff76969f4975dfd6acee872cc4ce58ece4230f9c54637f8d18eaeecc4549cc0232c603e2ea279491d13f5967cebd4198c980bbc1a1961c9fb6c6a0fde681623ad04596ddbbaf176fb8f0d3f6c5386b4c157100ac152faa593a4b30ee7c81a0ee1516e1d34e177784cbff5d9006d96104cafddee1e63954dadefd1c715cd30ff8a211ea85de27b7fdc64f03196bd4290f40feb440651d59a0e1b6648c400dad2f5376ab1ce4784f82bcaad740549b509b2029051d56786abcf251cfd30f26efaebb17497d7921b9cdeb08ba50116dbcb2fcae875d0c5bde55c8fa09c1f7f7193df678717538a52e4bbed2d39531859aaca89289746844991df79533fbd7fe89abf1d56813ec076e4e4b61889d4e44eaf024b1319d95f40dbae788f62a09ee651249ae9c6e29f96e1b27c22ed5bb1fa707cdbf233c5ee219ae76b7c8619a584f5de1974a6bc60f759332351a3004ae5a1394c48613a2f8b2295083bf4f2ee4bda9c40f34d389ec6e7cc1bfdcb003f10dd9c42068aa6f3fe28f579fe4f88904185eda4f190c8964edaaf5b28c7a4f7e5f403a33c1d53baed312e42693f7a1e0.

Mark W. Mahowald MD (2007) ‘Pathophysiologic mechanisms in REM sleep behavior disorder’, Current Neurology and Neuroscience Reports, 7(Issue 2), pp. 167–172. Available at: https://doi.org/10.1007/s11910-007-0013-7.

N.P. Robertson, K.J.P. (2014) ‘Narcolepsy: environment, genes and treatment’, 261(8), pp. 1644–1646. Available at: http://link.springer.com.libproxy.ucl.ac.uk/article/10.1007/s00415-014-7435-3/fulltext.html.

Saper, C.B. and Scammell, T.E. (2013) ‘Emerging therapeutics in sleep’, Annals of Neurology, 74(3), pp. 435–440. Available at: https://doi.org/10.1002/ana.24000.

Smith, K.S. and Rudolph, U. (2012) ‘Anxiety and depression: Mouse genetics and pharmacological approaches to the role of GABAA receptor subtypes’, Neuropharmacology, 62(1), pp. 54–62. Available at: https://doi.org/10.1016/j.neuropharm.2011.07.026.

Sodium oxybate: a primer for pharmacists in the treatment of narcolepsy (no date). Available at: https://www.researchgate.net/profile/Kimberley_Begley2/publication/265473606_Sodium_Oxybate_A_Primer_for_Pharmacists_in_the_Treatment_of_Narcolepsy/links/54dceb110cf25b09b912dd40.pdf.

Stores, G. (2003) ‘Medication for sleep-wake disorders’, Archives of Disease in Childhood, 88(10), pp. 899–903. Available at: https://doi.org/10.1136/adc.88.10.899.

Strange, P.G. (1992) Brain biochemistry and brain disorders. Oxford: Oxford University Press.